Cardiovascular Function in Adult Survivors of Childhood Malignancies

NCT01415999 | Completed

• 1 other identifier: UW 11-289
• Study Type: observational
• Target: 142
• Locations: 1 country
• Sites: 1

Brief Summary

Anthracyclines have been used commonly to treat children with solid tumours and haematological malignancies and have led to their increased survival. Nonetheless, anthracycline has the side effect of cardiotoxicity. The purpose of this study is to assess the impact of anthracycline therapy on heart deformation and fibrosis, heart-vessel interaction, usefulness of circulating biomarkers in the assessment of heart function and potential genetic predisposition to heart failure in adult survivors of childhood cancers.

Conditions

Childhood Cancers

Keywords

anthracycline; cardiac function; echocardiography; biomarkers

Study Arms (2)

patient

adult survivors of childhood malignancies

control

healthy age-matched individuals

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Patients will be recruited from the 5 public hospitals in Hong Kong (Prince of Wales Hospital, Princess Margaret Hospital, Queen Elizabeth Hospital, Queen Mary Hospital, and Tuen Mun Hospital) that treat the vast majority of childhood cancers, with the number of patients recruited from each hospital proportional to the respective new case-loads in the past 10 years.

You may qualify if:

• patients aged 18 to 35 years old
• history of acute leukaemia diagnosed before 18 years old
• completion of cancer directed therapy for at least 5 years.

You may not qualify if:

• history of congenital heart disease
• presence of syndromal disorder such as Down syndrome, neurofibromatosis, etc,
• hypothyroidism not on replacement therapy
• claustrophobia or other reasons rendering MRI assessment not feasible.

Sponsors & Collaborators

• The University of Hong Kong: lead

Study Sites (1)

Queen Mary Hospital

Hong Kong, Hong Kong, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

plasma, serum

Study Officials

• Yiu-fai Cheung, MD

  The University of Hong Kong

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: August 10, 2011
• First Posted: August 12, 2011
• Study Start: August 1, 2011
• Primary Completion: July 1, 2012
• Study Completion: July 1, 2012
• Last Updated: October 25, 2017

Record last verified: 2017-10

Locations

CN (1)